Nurses (ANCC)

Save-the-Date: Livestream: MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…

Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will…

Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life

The therapeutic landscape for HER2-neg metastatic breast cancer (HER2-neg MBC) is rapidly changing with the addition of antibody drug-conjugate (ADC) therapies.  As a result, clinicians are not confident or knowledgeable in applying emerging clinical data to…

MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively…

The Promise of Folate Receptor Alpha-Targeting ADCs for Platinum-Resistant Ovarian Cancer

Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…

Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events

As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…

All Hands on Deck: Spotlight on Clinical Advances in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers…

All Hands on Deck: A Focus on Current and Emerging Treatment Options in the Frontline Setting for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…

All Hands on Deck in Cervical Cancer Care: Screening, Treatment, and Equity Strategies to Improve Patient Lives

The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies…

All Hands on Deck – Utilizing JAK Inhibitors in Myelofibrosis Care: Evidence, Timing, and Strategic Approaches

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…